Close Menu

NEW YORK – Castle Biosciences said on Thursday that it has priced its underwritten public offering of 2 million shares of its common stock at $37 per share.

The Friendswood, Texas-based company expects gross proceeds of $74 million from the offering. In addition, Castle Bio has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of stock at the offering price. The offering is expected to close on June 29.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.